SpringerLink
Log in

Darmerkrankungen

Wie wirksam sind Probiotika bei Reizdarm, CED und C.-difficile-Infektionen?

  • Fortbildung
  • Published:
Gastro-News Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Germany)

Instant access to the full article PDF.

Institutional subscriptions

1

© J. F. Toader, A. Erhardt

2

© J. F. Toader, A. Erhardt

Literatur

  1. Stange EF. Intestinales Mikrobiom Und Innere Medizin. UNI-MED Verlag; 2021

  2. Layer P et al. Update S3-Leitlinie Reizdarmsyndrom: Definition, Pathophysiologie, Diagnostik und Therapie. Z Gastroenterol. 2021;59(12):1323-415. https://go.sn.pub/eFOO5v

  3. Ford AC et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol. 2014;109(10):1547-62

  4. Li B et al. Efficacy and safety of probiotics in irritable bowel syndrome: A systematic review and meta-analysis. Front Pharmacol. 2020;11

  5. Ringel-Kulka T et al. Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Benefit of the Probiotic Bifidobacterium infantis 35624 in Non-Patients With Symptoms of Abdominal Discomfort and Bloating. Am J Gastroenterol. 2017;112(1):145-51

  6. Pinto-Sanchez MI et al. Probiotic Bifidobacterium longum NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients With Irritable Bowel Syndrome. Gastroenterology. 2017;153(2):448-59.e8

  7. Guyonnet D et al. Aliment Pharmacol Ther. 2007;26(3):475-86

  8. Marteau P et al. Bifidobacterium animalis strain DN-173 010 shortens the colonic transit time in healthy women: a double-blind, randomized, controlled study. Aliment Pharmacol Ther. 2002;16(3):587-93

  9. Guglielmetti S, Mora D, Gschwender M, Popp K. Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life--a double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2011;33(10):1123-32

  10. Stevenson C et al. Nutrition. 2014;30(10):1151-7

  11. Nobaek S et al. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol. 2000;95(5):1231-8

  12. Niedzielin K et al. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2001;13(10):1143-7

  13. Fuke N et al. Effect of combined consumption of Lactobacillus brevis KB290 and β-carotene on minor diarrhoea-predominant irritable bowel syndrome-like symptoms in healthy subjects: a randomised, double-blind, placebo-controlled, parallel-group trial. Int J Food Sci Nutr. 2017;68(8):973-86

  14. Murakami K et al. The effect of Lactobacillus brevis KB290 against irritable bowel syndrome: a placebo-controlled double-blind crossover trial. Biopsychosoc Med. 2012;6(1)

  15. Lyra A et al. Irritable bowel syndrome symptom severity improves equally with probiotic and placebo. World J Gastroenterol. 2016;22(48):10631-42

  16. Sinn DH et al. Therapeutic effect of Lactobacillus acidophilus-SDC 2012, 2013 in patients with irritable bowel syndrome. Dig Dis Sci. 2008;53(10):2714-8

  17. Nobutani K et al. The effects of administration of the Lactobacillus gasseri strain CP2305 on quality of life, clinical symptoms and changes in gene expression in patients with irritable bowel syndrome. J Appl Microbiol. 2017;122(1):212-24

  18. Ojetti V et al. The effect of Lactobacillus reuteri supplementation in adults with chronic functional constipation: a randomized, double-blind, placebo-controlled trial. J Gastrointestin Liver Dis. 2014;23(4):387-91

  19. Niv E et al. The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome--a double blind, placebo-controlled, randomized study. Clin Nutr. 2005;24(6):925-31

  20. Koebnick C et al. Probiotic beverage containing Lactobacillus casei Shirota improves gastrointestinal symptoms in patients with chronic constipation. Can J Gastroenterol. 2003;17(11):655-9

  21. Thijssen AY et al. Efficacy of Lactobacillus casei Shirota for patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2016;28(1):8-14

  22. Majeed M et al. Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant Irritable Bowel Syndrome: a double blind randomized placebo controlled pilot clinical study. Nutr J. 2016;15(1)

  23. Dolin BJ. Effects of a proprietary Bacillus coagulans preparation on symptoms of diarrhea-predominant irritable bowel syndrome. Methods Find Exp Clin Pharmacol. 2009;31(10):655-9

  24. Hun L. Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS. Postgrad Med. 2009;121(2):119-24

  25. Enck Pet al. Randomized controlled treatment trial of irritable bowel syndrome with a probiotic E.-coli preparation (DSM17252) compared to placebo. Z Gastroenterol. 2009;47(2):209-14

  26. Abbas Z et al. Cytokine and clinical response to Saccharomyces boulardii therapy in diarrhea-dominant irritable bowel syndrome: a randomized trial. Eur J Gastroenterol Hepatol. 2014;26(6):630-9

  27. Pineton de Chambrun G et al. A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome. Dig Liver Dis. 2015;47(2):119-24

  28. Spiller R et al. Randomized double blind placebo-controlled trial of Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: improvement in abdominal pain and bloating in those with predominant constipation. United Eur Gastroenterol J. 2016;4(3):353-62

  29. Lorenzo-Zúñiga V et al. I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life. World J Gastroenterol. 2014;20(26):8709-16

  30. Ludidi S et al. Randomized clinical trial on the effect of a multispecies probiotic on visceroperception in hypersensitive IBS patients. Neurogastroenterol Motil. 2014;26(5):705-14

  31. Sisson G et al. Randomised clinical trial: A liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome - a 12 week double-blind study. Aliment Pharmacol Ther. 2014;40(1):51-62

  32. Yoon JS et al. Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Gastroenterol Hepatol. 2014;29(1):52-9

  33. Choi CH et al. Efficacy of combination therapy with probiotics and mosapride in patients with IBS without diarrhea: a randomized, double-blind, placebo-controlled, multicenter, phase II trial. Neurogastroenterol Motil. 2015;27(5):705-16

  34. Hod K et al. A double-blind, placebo-controlled study to assess the effect of a probiotic mixture on symptoms and inflammatory markers in women with diarrhea-predominant IBS. Neurogastroenterol Motil. 2017;29(7)

  35. Mezzasalma V et al. A Randomized, Double-Blind, Placebo-Controlled Trial: The Efficacy of Multispecies Probiotic Supplementation in Alleviating Symptoms of Irritable Bowel Syndrome Associated with Constipation. Biomed Res Int. 2016;2016. 4740907

  36. Yoon H et al. Effect of administering a multi-species probiotic mixture on the changes in fecal microbiota and symptoms of irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Clin Biochem Nutr. 2015;57(2):129-34

  37. Kim HJ et al. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil. 2005;17(5):687-96

  38. Kajander K et al. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment Pharmacol Ther. 2008;27(1):48-57

  39. Williams EA et al. Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2009;29(1):97-103

  40. Kaur L et al. Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2020;3(3):CD005573

  41. Iheozor-Ejiofor Z et al. Probiotics for maintenance of remission in ulcerative colitis. Cochrane database Syst Rev. 2020;3(3):CD007443

  42. Kruis W et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut. 2004;53(11):1617-23

  43. Losurdo G et al. Escherichia coli Nissle 1917 in Ulcerative Colitis Treatment: Systematic Review and Meta-analysis. J Gastrointestin Liver Dis. 2015;24(4):499-505

  44. Ghouri YAet al. Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease. Clin Exp Gastroenterol. 2014;7:473-87

  45. Shen J et al. Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn's disease, and pouchitis: meta-analysis of randomized controlled trials. Inflamm Bowel Dis. 2014;20(1):21-35

  46. RKI - RKI-Ratgeber - Clostridioides (früher Clostridium) difficile. Accessed March 14, 2023. https://go.sn.pub/W8al54

  47. Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med. 2002;346(5):334-9

  48. Europäische Leitlinie empfiehlt Fidaxomicin. Gastro-News 2022.;9(1):60

  49. Jafarnejad Set al. Probiotics Reduce the Risk of Antibiotic-Associated Diarrhea in Adults (18-64 Years) but Not the Elderly (>65 Years). Nutr Clin Pract. 2016;31(4):502-13

  50. Goldenberg JZ et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane database Syst Rev. 2017;12(12).CD006095

  51. Su GL et al. AGA Clinical Practice Guidelines on the Role of Probiotics in the Management of Gastrointestinal Disorders. Gastroenterology. 2020;159(2):697-705

  52. Mcfarland LV et al. A Randomized Placebo-Controlled Trial of Saccharomyces boulardii in Combination With Standard Antibiotics for Clostridium difficile Disease. JAMA J Am Med Assoc. 1994;271(24):1913-18

Download references

Author information

Authors and Affiliations

  1. Klinik für Gastroenterologie, Hepatologie, Diabetologie und Ernährungsmedizin, Petrus-Krankenhaus Wuppertal, Carnaperstraße 46, 42283, Wuppertal, Germany

    Justus Franz Toader &  Andreas Erhardt

Authors
  1. Justus Franz Toader
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andreas Erhardt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Justus Franz Toader.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Toader, J., Erhardt, A. Wie wirksam sind Probiotika bei Reizdarm, CED und C.-difficile-Infektionen?. Gastro-News 10, 40–45 (2023). https://doi.org/10.1007/s15036-023-3240-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15036-023-3240-0

Search

Navigation